NovoLog is a mealtime (rapid-acting) insulin. It’s a brand-name form of insulin aspart. For type 1 diabetes, you’ll typically inject NovoLog before your meals throughout the day. For type 2 diabetes, ...

On Feb. 14, the agency approved the drug, a biosimilar to Novolog, for glycemic control improvement in adult and pediatric diabetic patients. The subcutaneous medication is approved in a 3 milliliter, ...

Objective: Glycemic control using inhaled, dry-powder insulin plus a single injection of long-acting insulin was compared with a conventional regimen in patients with type 2 diabetes, which was ...

Treating children with mild diabetic ketoacidosis (DKA) using subcutaneous (SC) insulin aspart was linked to lower hospital costs and better efficacy of DKA management, compared with using intravenous ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Subcutaneous insulin therapy was associated with shorter ...

The expanded approval was based on data from the phase 3 PRONTO-PUMP-2 trial which evaluated Lyumjev vs Humalog for use in insulin pump therapy in 432 adults with type 1 diabetes. The Food and Drug ...

A revolutionary technology could dramatically improve the well-being of diabetic patients through a simple and straightforward way: an insulin oral delivery system that could replace traditional ...

Inhaled Technosphere insulin (TI) failed to meet noninferiority for HbA1c vs subcutaneous rapid-acting analog (RAA) insulin in youth.

Basaglar (insulin glargine) is a brand-name drug that’s used to help manage blood sugar levels in certain people. The drug comes as a liquid solution that’s injected under your skin. It’s usually ...

Overview: Insulin glargine is a long-acting insulin used to lower blood sugar levels in people with diabetes. It helps get sugar into your cells, so your body can use it for energy. The most common ...